Changes at the top for Karolinska Development
Sweden’s Karolinska Development (STO: KDEV) says that Bo Jesper Hansen, chairman of the company's board, has decided not stand for re-election at the 2017 Annual General Meeting.
Bo Jesper Hansen was appointed as chairman in 2013. Under his chairmanship, he initiated the successful transformation of Karolinska Development from a wide-ranging collection of early stage science-driven projects into a highly focused investment company with a portfolio of business-driven companies capable of delivering significant shareholder value.
"Bo Jesper Hansen's broad industry and leadership experience has been crucial in guiding Karolinska Development through the most significant changes in the Company's history. We would like to thank him for his considerable efforts that have created a strong platform for Karolinska Development's future success." said Niclas Adler, chairman of the nomination committee of Karolinska Development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze